Propanc Biopharma Receives Patent for Cancer Treatment in China

Propanc Biopharma (OTCQB:PPCB) announced it received notification of acceptance for its lead patent application from the Chinese Patent Office.
As quoted in the press release:

The acceptance of this key patent application is a first in China, representing yet another significant milestone for the Company, as it progresses its lead product, PRP, towards First-In-Human studies. Given that China accounts for more than 20% of the world’s population, significant growth in this pharmaceutical market is anticipated due to greater healthcare coverage for a rising middle class. The Company is considering filing a divisional application with the Chinese Patent Office to pursue additional claims based off the initial accepted application.
“Acceptance of our first Chinese patent is a significant achievement for our Company, and indicates the strong growth of intellectual property portfolio worldwide,” said James Nathanielsz, Propanc Biopharma’s Chief Executive Officer. “We continue to advance a number of different patent applications in key regions around the world. This provides a solid foundation for future licensing discussions. By having major regions and territories covered, it means we have greater flexibility selecting strategic partners, either by global reach, or local market penetration.”

Click here to read the full press release.